Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, Inc. and its executives, alleging that the company misrepresented its financial health and growth, leading to a significant decline in stock price in August 2025 [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, and seeks to recover damages for investors who incurred substantial losses during this timeframe [2]. Allegations of Misleading Information - The complaint indicates that on May 6, 2025, LifeMD reported strong first-quarter results and raised its full-year revenue and adjusted EBITDA guidance, claiming a "category-defining competitive moat" in virtual obesity care and strong performance from its RexMD brand [4]. - However, the lawsuit argues that this optimistic outlook was misleading as the company allegedly failed to disclose ongoing business challenges, including elevated customer acquisition costs and issues with patient refunds [5][10]. Stock Price Impact - Following the announcement of disappointing second-quarter results on August 5, 2025, which included missed revenue and earnings estimates and a reduction in full-year guidance, LifeMD's stock price fell by over 44% the next day [6][5]. Investigation by Hagens Berman - Hagens Berman, a national plaintiffs' rights firm, is investigating these claims on behalf of affected investors, focusing on whether LifeMD's management accurately represented the company's financial situation [7][8]. Key Issues Identified - The lawsuit highlights two main issues: rising customer acquisition costs in the RexMD segment and a higher-than-anticipated refund rate in the weight management business [10].

, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or acquired LifeMD securities during the Class Period may, no later than October 27, 2025, seek to be appointed as a lead plaintiff representative of the class. To lea ...

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of LifeMD, Inc. investors who were adversely affected by alleged securities fraud between May 7, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/lifemd-inc-lawsuit-submission-form?prid=169367&wire=4 Accessibility StatementSkip Navigation NEW YORK, Sept. 26, 2025 /PRNewswire/ -- Levi &Â Korsinsky, LLP notifies investors in LifeMD, Inc. ("LifeMD, Inc." or the ...

Company Overview - LifeMD, Inc. is a leading provider of virtual primary care services, offering telemedicine, laboratory and pharmacy access, and specialized treatment for over 200 conditions [2] - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, a state-of-the-art compounding pharmacy, and a U.S.-based patient care center to enhance access to high-quality and affordable care [2] Recent Developments - LifeMD announced its participation in the ROTH 4 Annual Healthcare Opportunities Conference scheduled for October 9, 2025, in New York City [1] - Management will engage in one-on-one meetings with investors throughout the conference [1] - Investors interested in attending can register by contacting their ROTH Capital Partners representative [1]

Core Viewpoint - Investors in LifeMD, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company's management regarding its competitive position and financial guidance [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that from May 7, 2025, to August 5, 2025, LifeMD's management materially overstated the company's competitive position [3]. - It is claimed that the management was reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [3]. - The positive statements made by the defendants about LifeMD's business operations and prospects were materially misleading and lacked a reasonable basis during the relevant period [3]. Group 2: Participation Information - Investors who suffered losses in LifeMD, Inc. are encouraged to contact the Law Offices of Howard G. Smith before October 27, 2025, to participate in the ongoing lawsuit [2][4]. - Interested parties can reach out via email, telephone, or visit the law firm's website for more information regarding their legal rights [2][4].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August 2025 [1][7]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7 to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance [5][6]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [5][6]. Financial Performance and Stock Impact - LifeMD reportedly faced rising customer acquisition costs in its RexMD segment and a higher-than-expected refund rate in its weight management business, which were not disclosed to investors [6]. - The situation escalated on August 5, 2025, when LifeMD announced second-quarter results that missed revenue and earnings per share estimates, leading to a drastic reduction in its full-year guidance. Following this announcement, the company's stock price dropped by over 44% [7]. Investor Actions - The lawsuit provides an opportunity for investors who incurred substantial losses during the specified period to seek recovery [8]. - Hagens Berman, the law firm investigating the claims, is looking into whether LifeMD was aware of but failed to disclose key operational issues [10].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its competitive position and financial guidance during the Class Period from May 7, 2025, to August 5, 2025 [2][3]. Allegation Details - The lawsuit claims that LifeMD's defendants overstated the company's competitive position and were reckless in raising the 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [3]. - It is alleged that the defendants' statements about LifeMD's business operations and prospects were materially false and misleading, leading to investor damages when the true information became public [3]. Next Steps - Investors who purchased LifeMD shares during the Class Period and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4].

LOS ANGELES--(BUSINESS WIRE)--LifeMD, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – LFMD. ...

Company Overview - LifeMD is a smaller player in the telehealth sector, positioning itself as a "direct-to-patient telehealth company" that offers a high-quality, cost-effective, and convenient way to access comprehensive virtual and in-home healthcare [1] Investment Insights - The focus on small-cap opportunities suggests a strategy aimed at finding asymmetric upside potential in the market, particularly through sustainable high dividend yields [2] - Key factors for investment consideration include insider buying, high insider ownership, a history of free cash flow growth, and substantial catalysts for turnaround [2] Analyst Position - The analyst has a beneficial long position in LifeMD shares, indicating confidence in the company's future performance [3]

Company Overview - LifeMD (NASDAQ: LFMD) is a smaller player in the telehealth sector, positioning itself as a "direct-to-patient telehealth company" that offers a high-quality, cost-effective, and convenient way to access comprehensive virtual and in-home healthcare [1] Investment Insights - The focus on small-cap opportunities suggests a strategy aimed at finding asymmetric upside potential in the market, particularly through sustainable high dividend yields [2] - Key investment criteria include insider buying, high insider ownership, a long history of free cash flow growth, and substantial catalysts for turnaround [2] Analyst Position - The analyst has a beneficial long position in LifeMD shares, indicating confidence in the company's future performance [3]